[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-442958-105":59,"doc-detail-442958-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","outcomes-of-people-living-with-acute-lymphoblastic-leukemia-who-received-inotuzumab-ozogamicin-before-a-stem-cell-transplant-plain-language-summary","Outcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell transplant - Plain Language Summary","","Plain language summary of real-world outcomes for people with acute lymphoblastic leukemia (ALL) who received inotuzumab ozogamicin and then underwent stem cell transplant. Reports overall survival at 18 months and the proportions of deaths related and unrelated to relapse. Summarizes the incidence of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) within 100 days and highlights higher VOD/SOS risk in those given two alkylator medicines for transplant preparation. Compares findings with clinical trials.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/outcomes-of-people-living-with-acute-lymphoblastic-leukemia-who-received-inotuzumab-ozogamicin-before-a-stem-cell-transplant-plain-language-summary/442958/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/outcomes-of-people-living-with-acute-lymphoblastic-leukemia-who-received-inotuzumab-ozogamicin-before-a-stem-cell-transplant-plain-language-summary/442958.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study population and what treatments did participants receive?","Question",{"text":112,"@type":113},"The study included people with acute lymphoblastic leukemia (ALL). Participants received inotuzumab ozogamicin and then underwent a stem cell transplant for their ALL.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What survival and death outcomes were reported after transplant?",{"text":117,"@type":113},"More than half (54%) were alive 18 months after transplant. Within 18 months, 22% died from reasons unrelated to relapse and 24% died from reasons related to relapse.",{"name":119,"@type":110,"acceptedAnswer":120},"How common was VOD/SOS and what affected the risk?",{"text":121,"@type":113},"About 14% developed VOD/SOS within 100 days of transplant. People given two alkylator medicines to prepare for transplant were more likely to develop VOD/SOS than those who were not.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},442958,1790792581,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Future  \nONCOLOGY  \nPlain Language Summary of Publication  \nOutcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell transplant: a plain language summary  \nMarcos de Limaa, Partow Kebriaeib, Francesco Lanzac, Christina Chod, Gizelle Popradie, Manmeet Kaurf, Mei-Jie Zhangf, Fan Zhangg,  \nRicha Shahh, Erik Vandendriesi, Kofi Asomaningi, Stephanie Dormanj, Matthias Stelljesk, David I. Marksl & Wael Saberf Author affiliations can be found at the end of this article.  \nFirst draft submitted: 18 December 2024; Accepted for publication: 15 October 2025  \nWhere can I find the original article on which this summary is based?  \nThis summary is based on an original article called ‘5-year real-world safety of inotuzumab ozogamicin before hematopoietic stem cell transplantation in B-cell precursor acute lymphoblastic leukemia.’ The original article was published in The American Journal of Hematology in 2025. You can read the original article for free at: [https://onlinelibrary.wiley.com/doi/10.1002/ajh.27637](https://onlinelibrary.wiley.com/doi/10.1002/ajh.27637) .  \nWhat is this summary about?  \nThis summary describes results from a real-world study that looked at people with a type of blood cancer called acute lymphoblastic leukemia (also known as ALL). People in the study received a medicine called inotuzumab ozogamicin (also known as inotuzumab) and then received a stem cell transplant for their ALL. Researchers looked at how long people in the study lived after their transplant and how many people died for reasons related and unrelated to relapse. They also looked at how many people developed side effects, including a potentially life-threatening condition called veno-occlusive disease or sinusoidal obstruction syndrome (also known as VOD/SOS) .  \nHow to say...  \n• Acute lymphoblastic leukemia:  \nuh-KYOOT LIM-foh-BLAS-tik loo-KEE-mee-uh  \n• ALL: A-ell-ell  \n• Bone marrow: bone MAYR-oh  \n• Inotuzumab ozogamicin:  \nih-noh-TOO-zoo-mab OH-zoh-ga-MIH-sin  \n• Lymphoblast: LIM-foh-BLAST  \n• Sinusoidal obstruction syndrome:  \nSINE-yoo-SOY-dul ub-STRUK-shun SIN-drome • Veno-occlusive: VEE-noh-uh-KLOO-siv  \nWhat were the results?  \nOver half the people (54%) in this study were alive 18 months after their transplant. Around 2 in 10 (22%) people died within 18 months of their transplant from reasons unrelated to relapse, and around 2 in 10 (24%) people died from reasons related to relapse.  \nAround 1 in 10 (14%) people in this study developed VOD/SOS within 100 days of their transplant. People who received two medicines called alkylators to prepare them for their transplant were more likely to develop VOD/SOS than those who did not.  \nWhat do the results mean?  \nIn this real-world study, the proportion of people with ALL who developed VOD/SOS after taking inotuzumab and receiving a stem cell transplant was similar to what has been observed in clinical trials. However, fewer people in this  \nreal-world study died from reasons unrelated to relapse than in clinical trials. People who received two medicines called alkylators to prepare them for their stem cell transplant were more likely to develop VOD/SOS.  \n10. 1080/14796694 .2025.2577005 © 2025 The Author(s) . Published by Informa UK Limited, trading as Taylor & Francis Group  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. For reprints and re-use requests, please contact: [t&freprints@tandf.co.uk](t&freprints@tandf.co.uk","cbCaibiLSIsWjdhu","https://ap.wps.com/l/cbCaibiLSIsWjdhu","pdf",1629195,11,"English","# Where can I find the original article on which this summary is based?\n# What is this summary about?\n# How to say...\n## Acute lymphoblastic leukemia / ALL / bone marrow / inotuzumab ozogamicin\n## Lymphoblast / Sinusoidal obstruction syndrome / Veno-occlusive\n# What were the results?\n# What do the results mean?\n# Key definitions","[{\"question\":\"What was the study population and what treatments did participants receive?\",\"answer\":\"The study included people with acute lymphoblastic leukemia (ALL). Participants received inotuzumab ozogamicin and then underwent a stem cell transplant for their ALL.\"},{\"question\":\"What survival and death outcomes were reported after transplant?\",\"answer\":\"More than half (54%) were alive 18 months after transplant. Within 18 months, 22% died from reasons unrelated to relapse and 24% died from reasons related to relapse.\"},{\"question\":\"How common was VOD/SOS and what affected the risk?\",\"answer\":\"About 14% developed VOD/SOS within 100 days of transplant. People given two alkylator medicines to prepare for transplant were more likely to develop VOD/SOS than those who were not.\"}]","Outcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell transplant - Plain Language Summary | PDF",1790702317,28]